AMERICAN ASSOCIATION FOR CANCER RESEARCH

CAREER DEVELOPMENT AWARDS

New Program to Support the Professional Development of Junior Faculty

Available to Cancer Researchers Around the World

Purpose: The AACR Career Development Awards in Cancer Research will be presented for the first time in 1999. These two-year, international awards support research by junior, tenure-track scientists, at the level of Assistant Professor, who are engaged in meritorious cancer research at an academic institution anywhere in the world. The AACR-National Foundation for Cancer Research Career Development Award is restricted to proposals in basic research related to any type of cancer. The AACR-Susan G. Komen Breast Cancer Foundation Career Development Award is restricted to proposals for basic, clinical, or translational research related to breast cancer, including epidemiological and prevention studies.

Support: The two-year, international grants provide $50,000 per year. The grant covers direct research expenses, which may include payments to research assistants. The grant is not intended to replace or supplement the salary of the primary investigator.

Sponsor: The AACR Career Development Awards are generously sponsored by the National Cancer Research Foundation and the Susan G. Komen Breast Cancer Foundation.

Eligibility

At the time of application, candidates must be in the first or second year of a full-time, tenure-tracked faculty appointment, at the level of Assistant Professor, in an academic institution anywhere in the world. Candidates must also have completed productive postdoctoral research and demonstrated independent, investigator-initiated research. Employees of a national government and employees of private industry are not eligible. Candidates must be nominated by a member of AACR and must be an AACR member or apply for membership by the time the fellowship application is submitted. AACR Associate Members may not be nominators.

Selection Process

Applications are evaluated by a prestigious, multi-disciplinary committee consisting of AACR Members who are experts in basic, clinical, prevention, and translational research. The application deadline is January 15, 1999.

More Information

The application form and complete guidelines can be requested by contacting AACR at the address below. The materials will soon be available at the AACR’s website, www.aacr.org.

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
ph: (215) 440-9300; f: (215) 440-9372
e-mail: horst@aacr.org
Attn: Jenny Anne Horst-Martz
EDUCATIONAL SESSIONS AND METHODS WORKSHOPS (SATURDAY AFTERNOON, APRIL 10, 1999)
To Be Announced

OFFICIAL OPENING EVENT (SUNDAY MORNING, APRIL 11, 1999)
Presidential Address (Webster K. Cavenee)
Plenary Session: New Frontiers in Cancer Research
Genetics (Robert A. Weinberg)
Immunology and Vaccines (Lloyd J. Old)
Therapeutics and Translational Research (Judah Folkman)
Hormonal Intervention and Prevention (C. Kent Osborne)
AACR-Pezcoller International Cancer Research Award Lecture
Special Lecture (James D. Watson)

SYMPOSIA
Animal Models for Human Cancer: Recent Developments, New Challenges (Tyler Jacks)
Advances in Chemoprevention (Raymond N. DuBois)
Infectious Agents and Cancer (Nancy E. Mueller)
Ubiquitin and Protein Degradation (Alexander J. Varshavsky)
Genomics, Genetics, and New Approaches to Cancer (Richard D. Klausner)
Transcriptional Regulation and Cancer (Lorraine J. Gudas)
Drug Discovery: From Basic Science to the Clinic (Daniel D. Von Hoff)
Cancer Vaccines (Ronald Levy)
DNA Repair (Richard D. Kolodner)
Telomeres, Centromeres, and Chromosomal Instability (Carol W. Greider)
Basic and Clinical Approaches to Ovarian Cancer (Robert C. Bast, Jr.)
Gene Environment Interactions in Cancer Etiology (Margaret R. Spitz and Kenneth Olden)
Apoptosis (Craig B. Thompson)
Molecular Targeted Therapy (John Mendelsohn)
Basic and Clinical Approaches to Lung Cancer (David Paul Carbone)
Diet and Cancer: Process and Paradox (John D. Potter)
Genetic Instability, DNA Damage, and Checkpoint Regulation (Geoffrey Wahl)
Invasion, Metastasis, and Angiogenesis (Isaiah J. Fidler)
Drug Resistance and Cell Cycle Abnormalities (Joseph R. Bertino)
Hormonally Related Tumors - Basic and Clinical Aspects (Bert W. O'Malley and Marc E. Lippman)
Late Breaking Science (Waun Ki Hong and Webster K. Cavenee)
Topoisomerasers in Carcinogenesis and Cancer Treatment (Leroy Fong Liu)
Replication and the Cell Cycle (Jacqueline A. Lees)
Future Directions in Research on Tobacco and Cancer (Virginia L. Ernster)
Advances in Stem Cell Gene Therapy (Cynthia E. Dunbar)

FORUMS
Tamoxifen: Risks and Benefits
Ethical and Legal Issues in Genetic Testing

"MEET-THE-EXPERT" SUNRISE SESSIONS
Drug Resistance (Susan P. C. Cole)
Cancer Screening (Barnett S. Kramer)
Molecular Signaling of CML (Jean Y. J. Wang)
Apoptosis and Chemotherapy (John A. Hickman)
Caspases (Nancy A. Thornberry)
Molecular Cytogenetics (Joe W. Gray)
p53 Gene Therapy-mediated Radio/Chemosensitization (Esther H. Chang)
Clinical and Molecular Genetics of Multiple Endocrine Neoplasia Type 2 (Bruce A. J. Ponder)
Differentiation Therapy (Samuel Waxman)
AIDS-related Malignancies (Ellen G. Feigal)
Tumor Vaccine Therapy (Michael T. Lotze)
Integration of Biological Agents into Radiotherapy (Chang W. Song)
Molecular Detection of Minimal Residual Disease (Theodore F. Zipf)
Microsatellite Instability (David Sidransky)
Chemoprevention Trials: Science vs. Art vs. Fantasy (David S. Alberts)
Genetic Imprinting (Andrew P. Feinberg)
Cancer Metastasis: Cellular and Clinical Studies (David Tarin)
Embryonal Stem-cell-based Technology (Randall Johnson)
Repetitive Senescence (Judith Campisi)
Drug Design and Development (Randall K. Johnson)
In Vivo Imaging of Gene Expression in Solid Tumors (Ralph Weissleder)
The RB Family and CDKs in the Cell Cycle in Cancer (Antonio Giordano)
Prospects for Biological Agents (Peter J. Houghton)
Disorders in Cell Circuity in Cancer (I. Bernard Weinstein)
bc1: Its Family and Modification (Timothy J. McDonnell)
Chemoprevention in Respiratory Cancer (Lee W. Wattenberg)
TGF-β and Colon Cancer (Sanford Markowitz)
Inherited Susceptibility to Breast and Ovarian Cancers (Fumi I. Olopade)
VEGF (Harold F. Dvorak)
Origins of Melanoma (Margaret A. Tucker)
Bioiology of Premalignant Lesions (Walter N. Hittelman)
Genetic Determinants of Prostate Cancer (William B. Isaacs)
DNA Repair: Breaking Cycle-specific Constraints in Combination Therapy (William K. Punktett)
Antisense Therapies (Stanley T. Crooke)
Topic to be Announced (Saijo Nagahito)
Small Molecule Inhibitors of Protein Kinases That Block Tumor Angiogenesis for the Treatment of Cancer and Metastasis (Jerry McMahon)
Integration of Biological Agents into Chemotherapy (Herbert M. Pinedo)
New Therapeutic Agents (Michaele C. Christian)
myc (Chi Van Dang)
Isolation of Genes Regulated by p53 or Beta-catenin and Their Roles in Human Carcinogenesis (Yusuke Nakamura)
Behavioral Oncology (Barbara K. Rimer)
Mdm2 (Guillermima Lozano)
Molecular Processes in DNA Repair After Irradiation (Gloria C. Li)
Natural Agents and Chemoprevention (Hirotta Fujitaki)
Genetics of Wilms Tumor (Michael R. DeBaun)
Update on Breast Cancer Treatment (Martin D. Aboloff)

PROGRAM COMMITTEE
Waun Ki Hong, Chairperson
Joseph F. Fraumeni, Jr., Co-Chairperson
Carol W. Greider, Co-Chairperson
Leroy F. Liu, Co-Chairperson

EDUCATION COMMITTEE
Jeffrey M. Trent, Chairperson
David S. Alberts, Chairperson

EXHIBITS COMMITTEE

LOCAL ARRANGEMENTS COMMITTEE
Robert F. Ozols, Chairperson

Further Information: AACR Office • Public Ledger Building, Suite 826 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483 • Telephone: 215-440-9300 • FAX: 215-440-9313 • E-mail: meetings@aacr.org • Website: http://www.aacr.org
MAYO CLINIC

Research on zinc finger transcriptional repressors, epithelial cell growth, and cancer. Postdoctoral position immediately available for a highly motivated individual to study the role of novel zinc finger proteins in transcriptional repression and in the regulation of normal and neoplastic pancreatic epithelial cell growth. The successful candidate will be part of a multidisciplinary team using state-of-the-art molecular and cell biological techniques. Applicant should have previous experience in protein chemistry and/or molecular biology. Send curriculum vitae and three references to:

Raul Urrutia, MD
GI Research Unit
Mayo Clinic, Alfred 2-435
200 First Street SW
Rochester, MN 55905
Fax: 507/255-6318, E-mail: urrutia.raul@mayo.edu

Mayo Foundation is an affirmative action and equal opportunity employer and educator.

DARTMOUTH MEDICAL SCHOOL
Department of Pathology

The Department of Pathology at Dartmouth Medical School is seeking an individual for a tenure-track position with an appointment as an assistant or associate professor. The search will concentrate on candidates holding M.D. or M.D./Ph.D. degrees who have completed pathology residency training. Post-doctoral research training in a recognized center with an investigative focus on cell-cycle control and/or transmembrane signaling in normal or neoplastic cells is strongly desired. The candidate should have a record of independent productivity and funding or a strong evidence of funding potential. It is envisioned that approximately 75% of the individual’s time will be devoted to basic research. Medical student teaching, administrative and clinical assignments can be arranged to accommodate the candidate’s requirements. The new faculty member will be expected to secure and maintain research funding, join the appropriate graduate training program, and direct an active research laboratory with the capacity to train Ph.D. candidates and post-doctoral fellows. Please send curriculum vitae, a research statement, and the names/addresses of three referees to:

William F. Hickey, M.D.
Professor and Chairman, Department of Pathology
Dartmouth Medical School—D.H.M.C.
Lebanon, NH 03756

Dartmouth College is an affirmative action, equal opportunity employer. Women and minorities are encouraged to apply.

PURDUE UNIVERSITY
Faculty Position in Cancer Research

The Department of Medicinal Chemistry and Molecular Pharmacology, in conjunction with the Purdue University Cancer Research Center and with support from the Walther Cancer Institute, invites applications from outstanding investigators for a tenure-track position at the level of ASSISTANT, ASSOCIATE or FULL PROFESSOR. This search represents part of an extensive, campus-wide expansion in basic cancer research programs at Purdue. The successful candidate will have established or will demonstrate the potential to establish a strong, extramurally funded, research program focusing on the cancer problem at the molecular level. The candidate will participate in one of three program areas of the NCI-designated Purdue Cancer Center (http://www.pharmacy.purdue.edu/~ccenter/): Cell Growth and Differentiation, Experimental Therapeutics and Diagnostics, or Structural Biology. The Department of Medicinal Chemistry and Molecular Pharmacology (http://www.pharmacy.purdue.edu/mcmp/mcmpdept.html) offers a vigorous research environment with first-rate analytical instrumentation. The candidate will have the opportunity to participate in excellent undergraduate and graduate educational and training programs. Minority and women scientists are especially encouraged to apply. Applicants should submit a curriculum vitae, a detailed description of research plans, and the names and addresses of three references to: Professor Robert L. Geahlen; Chair, Faculty Search Committee; Department of Medicinal Chemistry and Molecular Pharmacology; Hansen Life Sciences Research Building; Purdue University; West Lafayette, IN 47907. Review of candidates will begin on December 1, 1998 and continue until the position is filled. Purdue University is an Equal Opportunity/Equal Access Employer.

Postdoctoral Position

A Postdoctoral position is available in the Department of Neurosurgery at the University of Texas MD Anderson Cancer Center investigating the mechanisms of cell cycle control, apoptosis, and gene therapy in brain tumors.

Candidates should have a Ph.D. or M.D. with a strong background in biochemistry and molecular biology.

Send Curriculum Vitae with bibliography, summary of research experience, and the names, addresses, and phone number of three references to:

Frederick F. Lang, M.D.
Department of Neurosurgery
M.D. Anderson Cancer Center
1515 Holcombe Blvd., Box 64
Houston, Texas 77030

Equal Opportunity/Affirmative Action Employer. Women and minority candidates are strongly encouraged to apply. Smoke-free environment.
University of Vermont and Vermont Cancer Center is seeking to recruit two outstanding physician scientists at the Associate Professor level (tenure track) with active translational or applied clinical research programs in the areas of cancer treatment, diagnosis or chemoprevention. One position is available as part of an active and well-established translational breast cancer research program within the Cancer Center. A second physician scientist is sought whose disease focus is in breast, GI, GU or gynecologic cancers. Candidates must be board-certified in medical oncology or a related discipline with a track record of independent research funding and productivity. An emphasis on therapeutic trials is highly desirable. Successful candidates will be expected to generate external peer-reviewed funding, and significant protected time for research (80%) will be guaranteed with limited clinical service responsibilities. As members of the Vermont Cancer Center, an NCI-designated Comprehensive Cancer Center, successful candidates will benefit from direct and research infrastructure support from the Center and will have the opportunity to participate in ongoing basic, clinical and cancer prevention and control research programs. Active research programs or focus areas in the Center include: cell signalling and growth control, genome stability and expression, structural biology, neuro-oncology, experimental pathology, cancer prevention, familiar cancer genetics and breast cancer. UVM is an AA/EOE. Applications from women and people from diverse racial, ethnic and cultural backgrounds are encouraged. Applications accepted until January 1, 1999. Candidates should send a statement of research interests, CV and names of three referees to: Hyman B. Muss, M.D., Department of Medicine, UVM, Patrick 534, Fletcher Allen Health Care, 111 Colchester Avenue, Burlington, VT 05401. Fax: (802) 656-5946.
Faculty Position in Cancer Research
Department of Biological Sciences/
Cancer Center, Purdue University

The Department of Biological Sciences, together with the Purdue Cancer Center and the Walther Cancer Institute, is recruiting an individual at the assistant, associate or full professor level to fill one of several planned positions in cancer research at Purdue. Each of these positions will include highly competitive compensation packages, attractive research space and excellent start-up support. Applicants should have a research program that is focused on aspects of cancer genetics using molecular approaches in a mammalian system. Of particular interest are individuals using transgenic and knock-out strategies in the mouse to investigate mechanisms of transcriptional control, tumor suppressor/oncogene function or differentiation strategies aimed at tumor suppression. Successful candidates should have a Ph.D. in an appropriate discipline, significant postdoctoral experience and are expected to develop a vigorous, extramurally-funded research program and to participate in one of three program areas within the NCI-designated Purdue Cancer Center. The candidate also will have the opportunity to participate in excellent undergraduate and graduate educational and training programs within the Department of Biological Sciences. Applicants should send a curriculum vitae, a statement of research and teaching experience with future research goals and the names and addresses of three references to Stephen Konieczny, Search Committee Chair, Department of Biological Sciences, Purdue University, Lilly Hall of Life Sciences, West Lafayette, IN 47907-1392. Review of candidates will begin on December 1, 1998 and continue until the position is filled.

Purdue University is an Equal Opportunity/Affirmative Action Employer.

University of Arizona

The Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, invites applications for tenure-track positions at the assistant/associate professor level for the 1999-2000 academic year.

Applicants must have a doctoral degree and postdoctoral experience. Areas of preferred interest include but are not limited to: molecular toxicology related to drug metabolism or environmental toxicology; synthetic medicinal, combinatorial or natural products chemistry; molecular pharmacology. Experience with computer-assisted drug design, QSAR or molecular modeling is of additional interest.

Successful applicants must demonstrate the potential to develop/maintain a research program, obtain extramural funding and participate in teaching medicinal chemistry, toxicology, and/or pharmacology. Applicants for associate professor level must have current extramural funding. Faculty are affiliated with a large and highly competitive interdisciplinary graduate program and opportunities exist for participation in the Center for Toxicology and Arizona Cancer Center.

Review of applications will begin January 15, 1999, and will continue until the positions are filled. An application letter, curriculum vitae, copies of two publications, statement of research interests, and names and addresses of 3–5 references should be sent to:

Search Committee
Department of Pharmacology & Toxicology
College of Pharmacy/University of Arizona
PO Box 210207
Tucson, AZ 87521-0207
The University of Arizona is an EEO/AA Employer, M/W/D/V.

A New Resource Kit from the National Cancer Institute

Cancer Research
Because Lives Depend on It

To order this and other materials, call the Cancer Information Service, a program of the National Cancer Institute at

1-800-4-CANCER
(1-800-422-6237)

People with TTY equipment, dial 1-800-332-8615
PROFESSOR POSITIONS

The Ben May Institute for Cancer Research and the Department of Surgery at the University of Chicago are seeking applicants for tenure-track positions at the Assistant or Associate Professor level with expertise in molecular oncology. The ideal candidates will be an investigator with the ability to develop an independently funded research program in basic cancer biology, molecular genetics of cancers, or regulation of cell growth and differentiation. Candidates should have sufficient research experience to demonstrate both significant accomplishments and outstanding potential. The faculty member is expected to take advantage of the extensive collaborative interactions available with members of the University genetics, biochemistry, immunology and molecular biology community.

The Ben May Institute for Cancer Research (BMICR) is a basic research unit that for 45 years has been committed to the study of basic mechanisms of cancer and immunology. The Department of Surgery has a strong history of research in the field of oncology. The BMICR and Surgery are closely interfaced with the University of Chicago NCI-designated Comprehensive Cancer Center, the University of Chicago Center for Molecular Oncology and the Gwen Knapp Center for Lupus and Immunology Research. Additionally, these departments are closely affiliated with degree granting Committees on Immunology and Cancer Biology. Letters of recommendation including curriculum vitae, bibliography, a brief statement of research interest and the names of three references should be sent to: Jeffrey Bluestone, Chair, Search Committee, University of Chicago, 5841 S. Maryland Ave., MC6027, Chicago, IL 60637.

THE UNIVERSITY OF CHICAGO
An Affirmative Action/Equal Opportunity Employer

Postdoctoral Research Fellowship in Molecular Oncology

The Center for Molecular Medicine at the University of Connecticut School of Medicine invites applications for a postdoctoral fellowship to (a) pursue novel approaches toward understanding the role of the cyclin D1 onco-gene in human neoplasia and in relevant animal models, and (b) exploit this understanding for therapeutic purposes.

A strong background in molecular biology is required, and experience in molecular oncology is highly desirable.

Review of applications will begin on January 1, 1999, and will continue until the position is filled. Send curriculum vitae, statement of research experience and interests, and names of three references to:

Dr. Andrew Arnold
Director, Center for Molecular Medicine
University of Connecticut School of Medicine
263 Farmington Avenue
Farmington, CT 06030-1316

Rapid Access to Intervention Development “RAID”

The NATIONAL CANCER INSTITUTE is requesting applications for the following initiative: Rapid Access to Intervention Development (RAID). RAID will make available to academic investigators, on a competitive basis, the preclinical development contract resources of NCI’s Developmental Therapeutics Program. The goal of RAID is the rapid movement of novel molecules and concepts from the laboratory to the clinic for proof-of-principle clinical trials. RAID will assist investigators who submit successful applications by providing any (or all) of the preclinical development steps that may be obstacles to clinical translation. These may include, for example, production, bulk supply, GMP manufacturing, formulation, and toxicology. Suitable agents for RAID will include small molecules, biologics, or vaccines. There are two receipt dates for proposals per year, February 1 and August 1. Current applications must be received by February 1, with all materials submitted directly to the office listed below. For information on process and procedure, visit the web site, http://dtp.nci.nih.gov. Inquiries are encouraged, and the opportunity to clarify issues or questions is welcome. As of this cycle of applications, academic investigators may have collaborations with small-business partners and still qualify for RAID funding. Please note that a maximum of two distinct proposals per investigator can be submitted per the application review date. Please contact:

RAID, Office of Associate Director
Developmental Therapeutics Program, NCI
Executive Plaza North, Suite 843
6130 Executive Blvd., Rockville, MD 20852
Tel: 301.496.8720; Fax: 301.402.0831
Email: sausville@dtpax2.ncifcrf.gov
The September 1, 1998, cover of Cancer Research featured THE MARCH...Coming Together To Conquer Cancer™, an historic advocacy event which took place on September 25–26, 1998, at the National Mall in Washington, DC, and in virtually every city and state around the country. United in this unprecedented grassroots effort, hundreds of thousands of people participated in THE MARCH to express their grave concern about cancer and its devastating effects on all Americans and, in particular, to communicate to the Administration and to members of Congress that we must have the necessary resources NOW to address the cancer crisis. The message was loud and clear—cancer must become the Nation’s No. 1 research and health care priority. By all accounts, this event was very successful, and all those who actively contributed to the intensive preparations for THE MARCH are to be congratulated for their work. THE MARCH brought together cancer patients and cancer survivors, researchers and physicians, and many others in the ongoing struggle against cancer, and it was in large part responsible for the largest dollar increase in funding (for FY 1999) ever given to the NIH and the NCI. An upcoming special issue of AACR News will be devoted to this amazing show of support from the community for more funding for cancer research.

One of the most important initiatives of THE MARCH was the preparation of The March Research Task Force Report. This Report was commissioned by THE MARCH. Its release, the first post-rally initiative, should serve notice that this movement will not disappear just because the speeches on the Mall are now over and the buses have returned home from the Capitol. This issue of Cancer Research contains this seminal Report in its entirety (pages 5590–5627), and the cover appropriately highlights its publication and the two individuals who spearheaded and directed this extraordinary effort, Research Task Force Co-Chairpersons Anna D. Barker, Ph.D. (right), and Ellen V. Sigal, Ph.D. (left). Cancer Research is very proud to publish the Report and to provide the opportunity for its widest dissemination to the cancer community. It is required reading for every cancer researcher, every member of Congress, and indeed every citizen whose life has been touched by cancer.

The March Research Task Force was formed more than a year ago, almost immediately after THE MARCH was conceived. It consisted of more than 160 of the Nation’s leading cancer researchers and clinicians, cancer survivors, and advocates. The charge of the Research Task Force was "to distinguish the exceptional opportunities and needs in basic and clinical research that are critical to addressing the current and looming crisis of cancer incidence, mortality, and health care costs.” In determining what it would take to expedite cancer research if adequate resources were made available, the Research Task Force gave serious consideration to key barriers that must be removed to accelerate progress against cancer, including those that contribute to the disproportionate effect of cancer on minority and medically underserved populations.

The Research Task Force included leading scientists from the academic and private sectors, most of them members of the AACR. Thirteen subcommittees considered every aspect of cancer research, from the basic molecular biology of cancer to psychosocial research to unexplored opportunities in public-private partnerships. The findings of these subcommittees were then synthesized into the Report by Drs. Barker and Sigal.

Dr. Barker, President and CEO of BIO-NOVA, Inc., is a leading member of the AACR, serving as Chairperson of its Public Education Committee since 1993. She is renowned for her effective leadership in public education, public policy, and science policy. For many years, she has worked actively to bring together scientists and consumer advocates in the fight against cancer. As a result of her vast knowledge in science and public issues, and her unflagging dedication, she has been very successful in forging synergistic relationships between these two important sectors of the cancer community. Her unstinting passion about cancer and about the vital importance of research in accelerating progress against this disease has been the hallmark of her invaluable work in these areas.

Dr. Sigal, President of Sigal Development, is a tireless advocate for cancer research. The eradication of cancer is a primary mission in Dr. Sigal’s philanthropic and public pursuits. She founded and serves as Chairman of the Board of Friends of Cancer Research; this organization was formed to acknowledge the 25th Anniversary of the National Cancer Act and to emphasize the importance of cancer research in the conquest of this disease. She currently serves as President of the Creative Community Task Force for Cancer Research. She was a Presidential appointee to the National Cancer Advisory Board from 1992-98, and she served as Chair of the Budget and Planning Committee of the Board for over five years. Dr. Sigal is highly respected by cancer researchers for her many years of leadership and her unwavering personal commitment to the cure and prevention of cancer. She became an advocate for cancer research when she lost her sister to breast cancer. In this regard, she shares the same tragic family loss as Dr. Barker, who has lost both a sister and a mother to breast cancer.

Drs. Barker and Sigal credit the strength of the Report to the dedication of the individual members of the Research Task Force (whose names are listed in the Report) as well as to its Board of Directors, including: John R. Durant, M.D.; Margaret Foti, Ph.D.; Phillip A. Sharp, Ph.D.; and Ellen L. Stovall. We are all deeply grateful as well for the passion and moral support of the leadership of THE MARCH and its Chairman, Mr. Sidney Kimmel.

This Report can be distinguished from other blueprints for future cancer research in that The March Research Task Force was independent of any government or private agency concerns, and the Report represents the combined efforts of scientists, survivors, and private industry. It is also unique in its vision. It concludes, on the basis of the considered deliberations of the Research Task Force, that significant reductions in cancer incidence, mortality, and morbidity are possible in the next two decades—but only if the Nation is willing to make an annual investment averaging $10 billion per year over the next five years. Such an ambitious commitment of resources should be made deliberately and swiftly, with confidence in the conclusions of the Research Task Force. Special thanks are due to Drs. Barker and Sigal and to every member of this prestigious group for defining the problems, identifying solutions, and challenging all of us to ensure that our efforts are focused on the goal of eradicating cancer.

Webster K. Cavenee. Ph.D.
President, AACR